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Expansion of Serotype Coverage in the Universal Pediatric
Vaccination Calendar: Short-Term Effects on Age- and Serotype-
Dependent Incidence of Invasive Pneumococcal Clinical Presentations
in Madrid, Spain
Juan Picazo,a Jesus Ruiz-Contreras,b Juan Casado-Flores,c Sagrario Negreira,b Maria-Jesus García-de-Miguel,d
Teresa Hernández-Sampelayo,e Enrique Otheo,f Cristina Méndez,g on behalf of the HERACLES Study Group
Microbiology Department, Hospital Clínico San Carlos, Madrid, Spaina; Pediatric Department, Hospital 12 de Octubre, Madrid, Spainb; Pediatric ICU, Hospital Niño Jesús,
Madrid, Spainc; Pediatric Department, Hospital La Paz, Madrid, Spaind; Pediatric Department, Hospital Gregorio Marañón and CIBER of Respiratory Diseases (CibeRes),
Madrid, Spaine; Pediatric Department, Hospital Ramón y Cajal, Madrid, Spainf; Medical Department, Pfizer S.L.U., Alcobendas, Madrid, Spaing
InMadrid, Spain, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the pediatric universal vaccination
calendar in June 2010. A prospective clinical surveillance that included all children hospitalized with culture- and/or PCR-con-
firmed invasive pneumococcal disease (IPD) was performed in all Madrid hospitals. The incidence rates (IRs) (defined as the
number of cases/100,000 inhabitants aged<15 years) in the PCV7 (May 2007 to April 2010) versus PCV13 (May 2011 to April
2012) periods were compared. There were 499 cases in the PCV7 period and 79 cases in the PCV13 period. Globally, the IR signif-
icantly decreased from 17.09 (PCV7 period) to 7.70 (PCV13 period), with significant decreases (PCV7 versus PCV13 periods) in
all age groups for bacteremic pneumonia (5.51 versus 1.56), parapneumonic pneumococcal empyema (PPE) (5.72 versus 3.12),
andmeningitis (2.16 versus 0.97). In the PCV13 period, significant reductions (the IR in the PCV7 period versus the IR in the
PCV13 period) were found in IPDs caused by PCV13 serotypes (13.49 versus 4.38), and specifically by serotypes 1 (globally [4.79
versus 2.53], for bacteremic pneumonia [2.23 versus 0.97], and for PPE [2.26 versus 1.17]), serotype 5 (globally [1.88 versus 0.00],
for bacteremic pneumonia [0.89 versus 0.00], and for PPE [0.55 versus 0.00]), and serotype 19A (globally [3.77 versus 0.49], for
bacteremic pneumonia [0.72 versus 0.00], for PPE [0.89 versus 0.00], and for meningitis [0.62 versus 0.00]). IPDs caused by non-
PCV13 serotypes did not increase (IR, 3.60 in the PCV7 period versus 3.31 in the PCV13 period), regardless of age or presenta-
tion. No IPDs caused by the PCV13 serotypes were found in children who received 3 doses of PCV13. The number of hospitaliza-
tion days and sanitary costs were significantly lower in the PCV13 period. The switch from PCV7 to PCV13 in the universal
pediatric vaccination calendar provided sanitary and economical benefits without a replacement by non-PCV13 serotypes.
In the Madrid autonomous community (approximately 6 mil-lion inhabitants), the 7-valent pneumococcal conjugate vaccine
(PCV7) was included in the systematic childhood vaccination cal-
endar in November 2006 for the universal vaccination of children
aged24 months, with doses at 2, 4, 6, and 18 months of age. In
June 2010, the 13-valent vaccine (PCV13) replaced the PCV7,
with an immunization schedule of 2, 4, and 15 months and a
catch-up program for children aged 18 to 24 months.
The HERACLES study (1–4), a yearly clinical surveillance of all
pediatric laboratory-confirmed invasive pneumococcal disease
(IPD) requiring hospitalization in the autonomous community of
Madrid, Spain, started in May 2007, 6 months after the introduc-
tion of PCV7 in the pediatric calendar for universal vaccination.
Over the 6 years of this ongoing surveillance, successive yearly
analyses have shown that the incidence rate of total IPDs was not
reduced in the PCV7 era, despite the significant decreasing trend
of IPDs caused by PCV7 serotypes, due to the increase in IPDs by
non-PCV7 serotypes (mainly serotypes 1, 7F, and 19A) (4). In the
period immediately after the switch from PCV7 to PCV13 (2010
to 2011), significant reductions in the incidence rate of global IPD,
mainly achieved by the reduction of cases caused by serotypes 1
and 19A, were evidenced (4).
It has been postulated that a time lag after universal vaccina-
tion is necessary before disease rates stabilize and greater decreases
in IRs are shown compared to the baseline (5, 6). Mathematical
modeling has suggested a reduction in the overall incidence rate of
IPDs following the introduction of PCV13, with uncertainty
about serotype replacement (7). Early after the implementation of
PCV7, there was worldwide evidence of a rapid serotype replace-
ment, at different degrees, which reduced the overall effectiveness
of PCV7 (6, 8). Thus, monitoring IPD following PCV13 introduc-
tion is important, since the extent to which replacement occurs
after PCV13 universal vaccination is yet to be determined (9).
Considering, as a baseline, the incidence rates from the PCV7
universal vaccination era, the aim of this study was to compare the
incidence rates for all hospitalized IPDs during the PCV13 univer-
sal vaccination period (2011 to 2012) versus during the PCV7
universal vaccination period (2007 to 2010), with the analysis
measured by clinical presentation, serotype, and age groups.
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MATERIALS AND METHODS
A prospective active clinical surveillance study on laboratory-confirmed
IPD was carried out in all hospitals with pediatric departments located in
the autonomous community of Madrid (Spain), beginning in May 2007.
IPD was defined as the presence of Streptococcus pneumoniae in normal
sterile fluids, and only children aged 15 years with laboratory-con-
firmed IPD by culture and/or PCR were considered. The analysis was
performed by considering data from two periods: (i) a 3-year period (May
2007 to April 2010) of PCV7 universal vaccination (PCV7 period) and (ii)
a 1-year period (May 2011 to April 2012) starting 1 year after the switch
from PCV7 to PCV13 in May 2010 to ensure the completion of catch-up
vaccine administration (PCV13 period).
Basic demographic data (age, gender, and vaccination status) and clin-
ical presentation (bacteremic pneumonia, parapneumonic pneumococ-
cal empyema [PPE], primary bacteremia, meningitis, and others) were
recorded. Local research ethics committees approved the study protocol.
Written informed consent was obtained from parents or guardians before
inclusion of child participants in the study.
Samples were sent to the clinical microbiology laboratory at each cen-
ter for microbiological culture and/or PCR detection. All pneumococcal
isolates were sent to a single reference laboratory (Microbiology Depart-
ment of the University Clinic Hospital in Madrid) for serotyping by Quel-
lung reaction. Pleural and cerebrospinal fluids not yielding positive cul-
ture were also sent to the reference laboratory for PCR detection of the
pneumolysin (ply) and autolysin (lyt) genes (10, 11). Pneumococci that
were confirmed by PCR were serotyped by real-time PCR assay using the
LightCycler SYBR green format followed by melting-curve analysis, as
previously described (12), and detected serotypes 1, 3, 4, 5, 6, 7F, 14, 19A,
and 19F. The molecular typing of 19A isolates was carried out by multi-
locus sequence typing (MLST) as previously described (13), and sequence
types (STs) were allocated using the online MLST database (http://www
.mlst.net).
Susceptibilities to penicillin, cefotaxime, and erythromycin were de-
termined by microdilution according to CLSI recommendations (14).
Current CLSI breakpoints (15) were considered for susceptibility inter-
pretation. Isolates with intermediate- or high-level resistance were de-
fined as nonsusceptible.
The incidence rate (IR) was calculated as the number of cases per
100,000 inhabitants using estimated person-years data on children in
Madrid (for each study period, by age group, and for total children15
years of age) from the Spanish Instituto Nacional de Estadística (see http:
//www.ine.es/jaxiBD/tabla.do?per03&typedb&diviEPA&idtab26
1#nogo), shown in Table 1.
The sanitary costs for the different clinical presentations were ob-
tained from the Spanish Ministry of Health statistical website (http:
//msssi.gob.es/estadEstudios/estadisticas/cmbd.htm), which provides the
costs per hospitalized case based on codes from the International Classi-
fication of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
(16) in 2010 (more recent data are now available). The costs were directly
obtained, when available, or adapted from related processes. For pneu-
mococcal meningitis (code 320.1), the cost was 11,524.3 euros. The cost
for pneumococcal pneumonia (code 481), 4,330.75 euros, was considered
for bacteremic pneumonia, the cost for empyema (code 510), 6,743.42
euros, was considered for pneumococcal parapneumonic empyema, and
the cost for bacteremia (code 790.7), 4,994.38 euros, was considered for
primary bacteremia. The costs globally and per clinical presentation were
extrapolated to 100,000 inhabitants using person-years data from each
study period (Table 1).
The total days of hospitalization were calculated globally and per clin-
ical presentation and extrapolated to 100,000 inhabitants using person-
years data in each study period (Table 1).
Comparisons between the two study periods were performed with
Epidat version 3.1.
RESULTS
A total of 499 IPDs were identified in the 3-year PCV7 period and
79 IPDs in the 1-year PCV13 period. The median (interquartile
range) ages (in months) of children suffering with IPD were 32.0
(13.0 to 56.0) in the PCV7 period (56.1% males) and 40.0 (11.0 to
62.0) in the PCV13 period (48.1% males). Table 2 shows, by study
period, the number (IR) of total IPDs, bacteremic pneumonia,
PPE, primary bacteremia, and meningitis. Other presentations
(such as septic arthritis, peritonitis, cerebral abscess, periorbital
cellulitis, otomastoiditis, and periotic abscess) accounted for 48
cases in the PCV7 period and 10 cases in the PCV13 period.
PPE diagnoses were based exclusively on PCR (negative cul-
tures) in 102 out of 167 (61.1%) cases in 2007 to 2010 and in 22 out
TABLE 1 Estimated person-year data on children in Madrid for the
different study age groups by study period, according to the Spanish
Instituto Nacional de Estadística
Age group (mo)
No. of cases in:
2007 to 2010a 2011 to 2012
12 224,692 73,521
12 to24 221,154 75,200
24 to60 651,757 222,127
60 1,822,743 655,687
Total 2,920,346 1,026,535
a See reference 17. The person-years shown are summated values covering the first 3
years of the HERACLES study: 1st year, May 2007 to April 2008; 2nd year, May 2008 to
April 2009; and 3rd year, May 2009 to April 2010.
TABLE 2 Numbers (incidence rates) of overall IPDs by study period
and of the different clinical presentations by age group individually
Symptoms by age group
No. (IR) of cases in:
P2007 to 2010 2011 to 2012
Total IPDs 499 (17.09) 79 (7.70) 0.0000
12 mo 107 (47.62) 20 (27.20) 0.0260
12 to24 mo 89 (40.24) 11 (14.63) 0.0014
24 to60 mo 189 (29.00) 28 (12.61) 0.0000
60 mo 114 (6.25) 20 (3.05) 0.0034
Bacteremic pneumonia 161 (5.51) 16 (1.56) 0.0000
12 mo 13 (5.79) 3 (4.08) 0.8351
12 to24 mo 20 (9.04) 2 (2.66) 0.1124
24 to60 mo 80 (12.27) 6 (2.70) 0.0001
60 mo 48 (2.63) 5 (0.76) 0.0080
PPE 167 (5.72) 32 (3.12) 0.0019
12 mo 4 (1.78) 1 (1.36) 1.0000
12 to24 mo 30 (13.57) 2 (2.66) 0.0224
24 to60 mo 90 (13.81) 19 (8.55) 0.0710
60 mo 43 (2.36) 10 (1.53) 0.2728
Primary bacteremia 60 (2.05) 11 (1.07) 0.0595
12 mo 35 (15.58) 8 (10.88) 0.4572
12 to24 mo 13 (5.88) 3 (3.99) 0.7832
24 to60 mo 7 (1.07) 0 (0.00) 0.7135
60 mo 5 (0.27) 0 (0.00) 0.9995
Meningitis 63 (2.16) 10 (0.97) 0.0236
12 mo 36 (16.02) 4 (5.44) 0.0492
12 to24 mo 10 (4.52) 2 (2.66) 0.7583
24 to60 mo 5 (0.77) 1 (0.45) 1.0000
60 mo 12 (0.66) 3 (0.46) 0.8199
IPD Incidence following PCV7 to PCV13 Switching
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of 32 (68.8%) in 2010 to 2011. In the case of meningitis, diagnoses
were based exclusively on PCR (negative cultures) in 3 out of 63
(4.8%) cases in 2007 to 2010 and in 1 out of 10 (10.0%) in 2010 to
2011.
Figure 1 shows the yearly evolution of the IR of total IPDs, of
IPDs by PCV13 serotypes, and of IPDs by non-PCV13 serotypes
over the five HERACLES study periods.
IR by clinical presentation. In the PCV7 period, the IR of total
IPDs was 17.09. This IR significantly (P  0.0001) decreased to
7.70 in the PCV13 period, with significant (P 0.05) decreases for
all age groups (Table 2). The decrease in overall IPDs was due to
significant decreases in the IRs of bacteremic pneumonia (globally
and in children aged24 months) (P 0.01), PPE (globally and
in children aged12 to24 months) (P 0.05), and meningitis
(globally and in children aged 12 months) (P  0.05). The de-
crease in the IR of primary bacteremia did not reach significance
(P 0.0595).
The median age (in months) of children suffering from PPE
was significantly higher in the PCV13 period than in the PCV7
period (47.0 versus 42.0; P 0.032). In the case of meningitis, the
difference in mean age (17.5 months in the PCV13 period versus
8.0 months in the PCV7 period) did not reach statistical signifi-
cance (P 0.125), and no differences were found for bacteremic
pneumonia (45.0 versus 43.0 months, respectively; P 0.690) or
primary bacteremia (7.0 versus 8.0 months, respectively; P 
0.508).
IRby serotype.The reduction in the IR of total IPDs was due to
significant (P 0.01) reductions in IPDs caused by PCV13 sero-
types in all age groups (Table 3). The reduction found in the IR of
IPDs caused by PCV13 serotypes was due to significant reductions
in IPDs caused by serotype 1 (globally and in the group of children
aged24 to60 months) (P 0.01), serotype 5 (globally and in
children aged24 to60 months) (P 0.05), and serotype 19A
(globally and in children aged 60 months) (P  0.05). IPDs
caused by non-PCV13 serotypes did not increase in the PCV13
period either globally or in any of the age groups. The overall 105
cases caused by non-PCV13 serotypes in the PCV7 period were
caused by 25 different serotypes (none with 4 isolates/year),
while in the PCV13 period, the 34 cases were caused by 15 differ-
ent serotypes (serotype 22F [4 cases], 11A and 15B [3 cases each],
12F and 25A [2 cases each], and 20 cases of other serotypes).
The median age (in months) of children suffering from IPDs
caused by serotypes included in PCV13 was significantly higher in
the PCV13 period than in the PCV7 period (48.0 versus 34.5; P
0.037), mainly due to significant differences for serotype 1 (65.0
versus 52.0; P  0.016), without statistical significance for sero-
types 3 (37.5 versus 25.0; P  0.436), 7F (40.0 versus 22.0; P 
0.285), or 19A (14.0 versus 15.0; P 0.560).
IR by clinical presentation and serotype. Table 4 shows the
IRs of IPD clinical presentations caused by PCV7, by additional
serotypes in PCV13 (individually), by PCV13 (globally), and by
non-PCV13 serotypes for the different age groups in the study.
Reductions (P 0.05) in the IRs of meningitis, PPE, and bactere-
mic pneumonia were due to significant (P  0.01) reductions in
the IRs of these clinical presentations caused by PCV13 serotypes.
Specifically, significant reductions were found for meningitis
caused by serotype 19A (P 0.05), for PPE caused by serotypes 1
and 19A (P  0.05), and for bacteremic pneumonia caused by
serotypes 1, 5, and 19A (P 0.05). Although the reduction in the
IR of primary bacteremia did not reach statistical significance
(P  0.0595), the IR of primary bacteremia caused by PCV13
serotypes significantly (P  0.0061) decreased in the PCV13 pe-
riod.
The median age (in months) of children suffering from PPE
caused by serotypes included in the PCV13 was significantly
higher in the PCV13 period than in the PCV7 period (52.0 versus
44.0; P 0.028), mainly due to significant differences for serotype
1 (74.0 versus 49.5; P 0.002), without statistical significance for
other serotypes.
IPDs in the PCV13 period and relationship to vaccination
status. In the PCV13 period, 33 out of the 79 children with IPDs
had been vaccinated with at least one dose of PCV13. Of them, 12
suffered from an IPD by a serotype included in PCV13: one child
that had received only one dose (had primary bacteremia caused
by serotype 7F), 7 children that had received two doses (3 had
primary bacteremia caused by 19A-ST320, one had bacteremic
pneumonia caused by serotype 1, one had PPE caused by serotype
3, one had meningitis caused by serotype 1, and one had otomas-
toiditis caused by 19F), 3 children that had received one catch-up
dose (one had bacteremic pneumonia caused by serotype 3, one
had PPE caused by serotype 3, and one had a brain abscess related
to otomastoiditis caused by serotype 19A-ST320), and 1 child that
FIG 1 Yearly evolution of IRs of total IPDs, IPDs by PCV13 serotypes, and IPDs by non-PCV13 serotypes over the five HERACLES study time periods.
Picazo et al.
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had received the third PCV13 dose 2 days before hospital admis-
sion for an otomastoiditis and periotic abscess caused by serotype
19A-ST320. No further cases of IPDs caused by the PCV13 sero-
types were found in children that had been completely vaccinated
with PCV13 (3 doses).
Susceptibility. In the PCV13 period, all 19A isolates (n  5)
were nonsusceptible to cefotaxime and oral penicillin (3 of them
resistant to parenteral penicillin) and erythromycin, while all iso-
lates of serotypes 1 (n  26), 3 (n  6), and 7F (n  6) were
susceptible to oral penicillin.
Associated costs. Table 5 shows the total numbers of days of
hospitalization and sanitary costs per 100,000 inhabitants aged
15 years by clinical presentation in the two study periods. The
TABLE 3 Numbers (incidence rates) of IPDs caused by different
serotypes, by age group and study period
Serotype cause of IPDs by
age group
No. (IR) of cases in:
P2007 to 2010 2011 to 2012
PCV7 serotypes 21 (0.72) 2 (0.19) 0.0791
12 mo 4 (1.78) 2 (2.72) 0.9157
12 to24 mo 3 (1.36) 0 (0.00) 1.0000
24 to60 mo 4 (0.61) 0 (0.00) 1.0000
60 mo 10 (0.55) 0 (0.00) 0.3375
Serotypes added in PCV13
Serotype 1 140 (4.79) 26 (2.53) 0.0032
12 mo 6 (2.67) 1 (1.36) 0.9072
12 to24 mo 9 (4.07) 1 (1.33) 0.4714
24 to60 mo 71 (10.89) 9 (4.05) 0.0054
60 mo 54 (2.96) 15 (2.29) 0.4522
Serotype 3 24 (0.89) 6 (0.58) 0.5877
12 mo 5 (2.23) 1 (1.36) 1.0000
12 to24 mo 5 (2.26) 1 (1.33) 1.0000
24 to60 mo 12 (1.84) 4 (1.80) 1.0000
60 mo 2 (0.11) 0 (0.00) 1.0000
Serotype 5 55 (1.88) 0 (0.00) 0.0001
12 mo 11 (4.90) 0 (0.00) 0.3298
12 to24 mo 5 (2.26) 0 (0.00) 1.0000
24 to60 mo 24 (3.68) 0 (0.00) 0.0125
60 mo 15 (0.82) 0 (0.00) 0.0990
Serotype 6A 5 (0.17) 0 (0.00) 1.0000
12 mo 2 (0.89) 0 (0.00) 1.0000
12 to24 mo 2 (0.90) 0 (0.00) 1.0000
24 to60 mo 0 (0.00) 0 (0.00) 0.8875
60 mo 1 (0.05) 0 (0.00) 0.9182
Serotype 7F 39 (1.44) 6 (0.58) 0.0770
12 mo 12 (5.34) 1 (1.36) 0.1121
12 to24 mo 8 (3.62) 0 (0.00) 0.5828
24 to60 mo 14 (2.15) 5 (2.25) 1.0000
60 mo 5 (0.27) 0 (0.00) 0.9995
Serotype 19A 110 (3.77) 5 (0.49) 0.0000
12 mo 37 (16.47) 2 (2.72) 0.0082
12 to24 mo 37 (16.73) 2 (2.66) 0.0065
24 to60 mo 26 (3.99) 1 (0.45) 0.0178
60 mo 10 (0.55) 0 (0.00) 0.3375
PCV13 serotypes 394 (13.49) 45 (4.38) 0.0000
12 mo 85 (37.83) 8 (10.88) 0.0005
12 to24 mo 61 (27.58) 3 (3.99) 0.0003
24 to60 mo 151 (23.17) 19 (8.55) 0.0000
60 mo 97 (5.32) 15 (2.29) 0.0025
Non-PCV13 serotypes 105 (3.60) 34 (3.31) 0.7494
12 mo 30 (13.35) 13 (17.68) 0.5017
12 to24 mo 20 (9.04) 7 (9.31) 0.8765
24 to60 mo 38 (5.83) 9 (4.05) 0.4124
60 mo 17 (0.93) 5 (0.76) 0.9077
TABLE 4 Numbers (incidence rates) of different clinical presentations
caused by different serotypes globally and by study period
Presentation and
serotype
No. (IR) of cases in:
P2007 to 2010 2011 to 2012
Total IPDs 499 (17.09) 79 (7.70) 0.0000
PCV7 21 (0.72) 2 (0.19) 0.0791
1 140 (4.79) 26 (2.53) 0.0032
3 24 (0.89) 6 (0.58) 0.5877
5 55 (1.88) 0 (0.00) 0.0001
6A 5 (0.17) 0 (0.00) 1.0000
7F 39 (1.44) 6 (0.58) 0.0770
19A 110 (3.77) 5 (0.49) 0.0000
PCV13 394 (13.49) 45 (4.38) 0.0000
Non-PCV13 105 (3.60) 34 (3.31) 0.7494
Bacteremic pneumonia 161 (5.51) 16 (1.56) 0.0000
PCV7 7 (0.24) 0 (0.00) 0.6849
1 65 (2.23) 10 (0.97) 0.0178
3 4 (0.14) 1 (0.10) 1.0000
5 26 (0.89) 0 (0.00) 0.0154
6A 0 (0.00) 0 (0.00) 0.9051
7F 16 (0.55) 1 (0.10) 0.0833
19A 21 (0.72) 0 (0.00) 0.0231
PCV13 139 (4.76) 12 (1.17) 0.0000
Non-PCV13 22 (0.75) 4 (0.39) 0.3118
PPE 167 (5.72) 32 (3.12) 0.0019
PCV7 7 (0.24) 0 (0.00) 0.6849
1 66 (2.26) 12 (1.17) 0.0444
3 15 (0.51) 5 (0.49) 1.0000
5 16 (0.55) 0 (0.00) 0.0833
6A 0 (0.00) 0 (0.00) 0.9051
7F 9 (0.31) 4 (0.39) 0.8991
19A 26 (0.89) 0 (0.00) 0.0154
PCV13 139 (4.76) 21 (2.05) 0.0003
Non-PCV13 28 (0.96) 11 (1.07) 0.8964
Primary bacteremia 60 (2.05) 11 (1.07) 0.0595
PCV7 3 (0.10) 0 (0.00) 1.0000
1 3 (0.10) 0 (0.00) 1.0000
3 2 (0.07) 0 (0.00) 1.0000
5 6 (0.21) 0 (0.00) 0.8403
6A 1 (0.03) 0 (0.00) 0.9051
7F 9 (0.31) 1 (0.10) 0.4441
19A 22 (0.75) 3 (0.29) 0.1574
PCV13 46 (1.58) 4 (0.39) 0.0061
Non-PCV13 14 (0.48) 7 (0.68) 0.5860
Meningitis 63 (2.16) 10 (0.97) 0.0236
PCV7 2 (0.07) 0 (0.00) 1.0000
1 2 (0.07) 1 (0.10) 1.0000
3 1 (0.03) 0 (0.00) 0.9051
5 4 (0.14) 0 (0.00) 1.0000
6A 3 (0.10) 0 (0.00) 1.0000
7F 4 (0.14) 0 (0.00) 1.0000
19A 18 (0.62) 0 (0.00) 0.0500
PCV13 34 (1.16) 1 (0.10) 0.0034
Non-PCV13 29 (0.99) 9 (0.88) 0.8873
IPD Incidence following PCV7 to PCV13 Switching
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number of days of hospitalization per 100,000 inhabitants aged
15 years and the sanitary costs per 100,000 inhabitants aged15
years were significantly lower in the PCV13 period for IPDs glob-
ally and for the four major presentations individually. The reduc-
tions in the days of hospitalization per 100,000 inhabitants aged
15 years from the PCV7 to the PCV13 period were 47.4% glob-
ally, 79.3% for bacteremic pneumonia, 42.1% for PPE, 46.0% for
primary bacteremia, 35.5% for meningitis, and 19.2% for other
presentations. The estimated approximate reductions in sanitary
costs per 100,000 inhabitants aged15 years in the PCV13 period
were 53,000 euros globally, 17,000 euros for bacteremic pneumo-
nia, 17,500 euros for PPE, 4,900 euros for primary bacteremia, and
13,600 euros for meningitis.
DISCUSSION
The incidence data regarding IPDs vary widely depending on vac-
cination policy, geographical areas, and differences in the study
methodologies and surveillance systems (17, 18). In Spain, where
PCV7 was introduced in 2001 in the private market, the differ-
ences between geographical areas are evident according to the
published data. The incidence rates of IPDs in children aged 2
years were reduced in the Basque Country and Navarre from 93.5
(1998 to 2001) to 56.3 (2003), with a vaccine uptake of 28% and
45%, respectively, with significant reductions in pneumococcal
meningitis and pneumococcal bacteremia, and also in children
aged 5 years (19). In Barcelona, the incidence rates of IPDs in
children decreased from 96.9 in 1999 to 90.6 in 2004, with one-
third of children having received PCV7, and with significant re-
ductions in meningitis and bacteremia but increases in empyema
(20). Interestingly, another study in Barcelona showed a signifi-
cant increase in the incidence of IPDs in children aged5 years,
from 76.2/100,000 inhabitants in 2007 to 109.9/100,000 inhabit-
ants in 2009, due to the increase in cases caused by non-PCV7
serotypes (21). Similar incidence rates (61.55/100,000 inhabit-
ants) were reported in the autonomous community of Madrid in
the period of 1998 to 2006 (prior to PCV7 inclusion in the system-
atic vaccination calendar for childhood immunizations) (22).
These values contrast with the IRs of IPDs in the PCV7 period of
the present study: 17.09 globally (15 years) and 47.62 in children
aged 12 months. The decrease reported for the period 2007 to
2011 (4) has continued, leading to IRs of 7.70 (global IPDs) and
27.2 (children aged 12 months) in the present yearly analysis
(2011 to 2012) of the HERACLES study. The decrease in the
PCV13 period was significant for all pediatric age groups and for
bacteremic pneumonia, PPE, and meningitis, with IRs of 1.56,
3.12, and 0.97, respectively, in 2011 to 2012.
IPD incidence is age dependent. The results of the present
study suggest that due to PCV13 vaccination of the youngest chil-
dren, the mean age of children suffering from IPDs has increased.
Nevertheless, probably due to the limited number of cases, statis-
tical significance was only found in the case of PPE and, among
them, for serotype 1 cases. There has been a significant reduction
in PPE cases among children aged12 to24 months, a pop-
ulation group that had been vaccinated with PCV13 the previ-
ous year, but not among older children that were not in the
target population for vaccination. Previous articles from the
HERACLES study had shown that serotype 1 was linked to
respiratory presentations of IPD and children aged 36 months
(1). In the present analysis, respiratory presentations (bacteremic
pneumonia and PPE) were the most prevalent IPDs in both peri-
ods (65.72% in the PCV7 period and 60.76% in the PCV13 pe-
riod). However, the similar distributions of bacteremic pneumo-
nia and PPE in the PCV7 period changed in the PCV13 period,
with bacteremic pneumonia comprising 20.25% of total IPDs and
PPE 40.51% of total IPDs. In any case, the IRs of IPD caused by
serotypes 1 and 19A have markedly decreased, without any cases
of bacteremic pneumonia, PPE, and meningitis caused by sero-
type 19A in the PCV13 period. Serotype 19A was linked to non-
respiratory presentations and children aged 12 months in the
PCV7 era (1). The five serotype 19A cases in the PCV13 period of
the present analysis were primary bacteremia (3 cases) and 2 IPDs
linked to otic foci. All isolates belonged to ST320. The marked
reduction in serotype 19A cases is important from the point of
view of antibiotic resistance, since in our country, ST320 is a wor-
risome clone showing multidrug resistance (2, 23, 24).
The significant reduction in the IR of serotype 5, without any
cases in 2011 to 2012, could not be attributed only to vaccine
pressure, since although this serotype was the third most prevalent
(after serotypes 1 and 19A) in the PCV7 period, it has been linked
to community outbreaks (25), such as that which occurred in the
autonomous community of Madrid in the PCV7 period.
In a previous study using real-time PCR for identification, se-
rotype 3 was reported to be a common serotype causing IPD in
children in Spain (26). In the present analysis, cases caused by
serotype 3 represented8% in both periods, without a significant
reduction in IR in the PCV13 period. No variations over 3 decades
were described for this serotype, despite its high antimicrobial
susceptibility as shown in Spain in a previous study (27). The
inclusion of this serotype in PCV13 will probably have epidemio-
logical effects once a time lag period passes after universal PCV13
vaccination, since none of the six cases of IPD caused by serotype
3 occurred in children who had received the 3-dose schedule of
PCV13.
In the present study, no PCV13 vaccine failures were detected
with use of the complete vaccination schedule, since the child with
otomastoiditis by serotype 19A had received the third PCV13 dose
only 2 days before hospital admission.
Of high importance is that, according to data in the present
study, the IR of IPDs caused by non-PCV13 serotypes did not vary
TABLE 5 Total numbers of days of hospitalization per 100,000
inhabitants aged15 years and sanitary costs by clinical presentation in
the two study periods
Clinical
presentation
2007 to 2010 2011 to 2012
No. of days of
hospitalization
Sanitary
costs (€)d
No. of days of
hospitalization
Sanitary
costs (€)d
Bacteremic
pneumonia
51.36 23,875.62 10.62a 6,750.09a
PPE 105.43 38,562.25 61.08a 21,021.15a
Primary bacteremia 16.23 10,261.21 8.77a 5,351.81a
Meningitis 43.21 24,861.13 27.86a 11,226.41a
Othersb 19.52 15.78c
Total IPDs 235.76 97,560.21 124.11a 44,349.46a
a P 0.0001 versus 2007-2010 period.
b Other presentations (such as septic arthritis, peritonitis, cerebral abscess, periorbital
cellulitis, otomastoiditis and periotic abscess) accounted for 48 cases in the PCV7
period and 10 cases in the PCV13 period.
c P 0.0188 versus that for 2007-2010 period.
d For calculations of sanitary costs, only bacteremic pneumonia, PPE, primary
bacteremia, and meningitis were considered.
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after the switch from PCV7 to PCV13. Thus, the replacement issue
detected early after the PCV7 introduction affecting both carriage
and disease (9), which created uncertainty about replacement ef-
fects after PCV13 introduction, was not detected in the present
study. No increase in cases caused by non-PCV13 serotypes was
found in the PCV13 period for the four major clinical presenta-
tions studied, with the IRs of IPD by non-PCV13 serotypes being
1. In addition, the 34 non-PCV13 cases found in 2011 to 2012
were caused by 15 different serotypes, none of them with4 iso-
lates, suggesting no specific serotype to be a potential candidate
for future serotype replacement.
The incidence rates of global IPD (IR, 17.0) and of IPD by
PCV13 serotypes (IR,13.5) remained unchanged from 2007 to
2010 (4). In contrast, there was a significant reduction in disease
demonstrated in the present study after the switch from PCV7 to
PCV13 for universal vaccination. This substantial reduction was
linked to significant reductions in the estimated sanitary costs per
100,000 inhabitants aged15 years and in days of hospitalization
per 100,000 inhabitants for IPDs globally and for the four major
presentations individually. Previous mathematical modeling of
the long-term effects of replacing PCV7 with PCV13 showed the
cost-effectiveness of such a switch in England and Wales (7), as
well as of the implementation of PCV13 universal vaccination by
the public health system in Valencia, Spain (28).
The results of the present analysis provide useful evidence on
the benefits of replacing PCV7 with PCV13 universal vaccination.
This is important since, at least with PCV7, stopping universal
vaccination is predicted to cause a rebound in the number of IPD
cases to the pre-PCV7 level (7). In the present study, no replace-
ment by non-PCV13 serotypes was found in serotypes causing
IPDs in the PCV13 period. However, if a possible replacement
effect occurs, it is unlikely that this might lead to scenarios where
PCV13 universal vaccination becomes less beneficial than the op-
tion of discontinuing conjugate vaccination altogether (7).
ACKNOWLEDGMENTS
This work was supported in part by an unrestricted grant from Pfizer
S.L.U., Madrid, Spain.
J.P. and J.R.-C. have received travel fees from Pfizer for attending
and/or speaking at symposiums and congresses. C.M. is an employee of
Pfizer S.L.U., Madrid, Spain. The other authors have no conflicts of inter-
est or funding to disclose.
Other members of the HERACLES study group include A. Delgado-
Iribarren and M. Bueno (Hospital Universitario Fundación de Alcorcón),
A. Alhambra and M. T. García (Hospital Sanchinarro), A. Rivas-Castillo
and P. Fernandez (Hospital San Rafael), A. Gutiérrez (Hospital La Paz), B.
Hernández (Hospital Niño Jesús), M. Zafra and J. Jaqueti (Hospital de
uenlabrada), E. Rios, E. Culebras, F. González, and I. Rodriguez-Avial
(Hospital Clínico San Carlos), C. Calvo and I. Wilhelmi (Hospital Severo
Ochoa), C. Serrano and E. Garcia-Peñuela (Hospital de la Zarzuela), E.
Bouza and E. Cercenado (Hospital Gregorio Marañón and CIBER of Re-
spiratory Diseases [CIBERES]), E. Gomez (Hospital Ramón y Cajal), F.
Sanz, E. Giangaspro, and I. Sánchez (Hospital 12 de Octubre), I. Gadea
and M. N. Dominguez (Fundación Jiménez Díaz), I. Romero and A. Al-
hambra (Hospital de Torrelodones), J. L. Gómez-Garcés and M. A. Roa
(Hospital de Móstoles), J. T. Ramos and J. Cacho (Hospital de Getafe),
J. C. Sanz (LRSP), M. L. García-Picazo and S. Gallego (Hospital de El
Escorial), M. J. Cilleruelo and M. I. Sánchez (Hospital Puerta de Hierro),
P. Gomez and M. Penín (Hospital Príncipe de Asturias), S. Salso and M.
Corcino (Hospital de Montepríncipe), A. Rodriguez (Hospital del Sur-
este), J. Clemente (Hospital del Henares), J. L. Ruibal (Hospital Infanta
Cristina), F. J. Sanz and J. Zapardiel (Hospital Infanta Elena), B. Agundez
(Hospital Infanta Leonor), A. Cañete (Hospital Infanta Sofia), C. Garcia-
Vao (Hospital del Tajo), A. Sanchez (BR. Salud), A. García-Sampedro, C.
Balseiro, and M. del Amo (Pfizer S.L.U.), M. J. Giménez and L. Aguilar
(University Complutense), Madrid, Spain.
REFERENCES
1. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Del Castillo
F, Hernández-Sampelayo T, Otheo E, Balboa F, Ríos E, Méndez C,
Heracles Study Group. 2011. Relationship between serotypes, age, and
clinical presentation of invasive pneumococcal disease in Madrid, Spain,
after introduction of the 7-valent pneumococcal conjugate vaccine into
the vaccination calendar. Clin. Vaccine Immunol. 18:89 –94.
2. Picazo J, Ruiz-Contreras J, Hernandez B, Sanz F, Gutierrez A, Cerce-
nado E, Meseguer MA, Delgado-Iribarren A, Rodriguez-Avial I, Mén-
dez C. 2011. Clonal and clinical profile of Streptococcus pneumoniae sero-
type 19A causing pediatric invasive infections: a 2-year (2007-2009)
laboratory-based surveillance in Madrid. Vaccine 29:1770 –1776.
3. Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Del Castillo F,
Hernández-Sampelayo T, Bueno M, Calvo C, Ríos E, Méndez C,
HERACLES Study Group. 2011. Laboratory-based, 2-year surveillance of
pediatric parapneumonic pneumococcal empyema following heptavalent
pneumococcal conjugate vaccine universal vaccination in Madrid. Pedi-
atr. Infect. Dis. J. 30:471– 474.
4. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-
Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C. 2013. Impact
of introduction of conjugate vaccines in the vaccination schedule on the
incidence of pediatric invasive pneumococcal disease requiring hospital-
ization in Madrid 2007 to 2011. Pediatr. Infect. Dis. J. 32:656 – 6561.
5. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM,
Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW,
Whitney CG, Moore MR, Active Bacterial Core Surveillance/Emerging
Infections Program Network. 2010. Sustained reductions in invasive
pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201:
32– 41.
6. Fitzwater SP, Chandran A, Santosham M, Johnson HL. 2012. The
worldwide impact of the seven-valent pneumococcal conjugate vaccine.
Pediatr. Infect. Dis. J. 31:501–508.
7. Choi YH, Jit M, Flasche S, Gay N, Miller E. 2012. Mathematical
modelling long-term effects of replacing Prevnar7 with Prevnar13 on in-
vasive pneumococcal diseases in England and Wales. PLoS One 7:e39927.
doi:10.1371/journal.pone.0039927.
8. Isaacman DJ, McIntosh ED, Reinert RR. 2010. Burden of invasive pneu-
mococcal disease and serotype distribution among Streptococcus pneu-
moniae isolates in young children in Europe: impact of the 7-valent pneu-
mococcal conjugate vaccine and considerations for future conjugate
vaccines. Int. J. Infect. Dis. 14:e197– e209. doi:10.1016/j.ijid.2009.05.010.
9. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. 2012. Pneumococcal
13-valent conjugate vaccine for the prevention of invasive pneumococcal
disease in children and adults. Expert Rev. Vaccines 11:889 –902.
10. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski
EB. 2001. Simultaneous detection of Neisseria meningitidis, Haemophilus
influenzae, and Streptococcus pneumoniae in suspected cases of meningitis
and septicemia using real-time PCR. J. Clin. Microbiol. 39:1553–1558.
11. Carvalho MdaGS, Tondella ML, McCaustland K, Weidlich L, McGee L,
Mayer LW, Steigerwalt A, Whaley M, Facklam RR, Fields B, Carlone G,
Ades EW, Dagan R, Sampson JS. 2007. Evaluation and improvement of
real-time PCR assays targeting lytA, ply, and psaA genes for detection of
pneumococcal DNA. J. Clin. Microbiol. 45:2460 –2466.
12. Sanz JC, Culebras E, Ríos E, Rodríguez-Avial I, Wilhelmi I, Ramos B,
Ordobás M, Picazo JJ. 2010. Direct serogrouping of Streptococcus pneu-
moniae strains in clinical samples by use of a latex agglutination test. J.
Clin. Microbiol. 48:593–595.
13. Enright MC, Spratt BG. 1998. A multilocus sequence typing scheme for
Streptococcus pneumoniae: identification of clones associated with serious
invasive disease. Microbiology 144:3049 –3060.
14. Clinical and Laboratory Standards Institute. 2006. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically—
seventh edition. Approved standard M7-A7. Clinical and Laboratory
Standards Institute, Wayne, PA.
15. Clinical and Laboratory Standards Institute. 2009. Performance stan-
dards for antimicrobial susceptibility testing; 19th informational supple-
IPD Incidence following PCV7 to PCV13 Switching
October 2013 Volume 20 Number 10 cvi.asm.org 1529
 o
n
 O
ctober 1, 2014 by UAM
/SERVICIO
 DE DO
CUM
ENTACIO
N
http://cvi.asm
.org/
D
ow
nloaded from
 
ment. CLSI M100-S19. Clinical and Laboratory Standards Institute,
Wayne, PA.
16. Ministerio de Sanidad y Consumo. 2010. Clasificación internacional de
enfermedades: CIE 9 MC (7a ED). Ministerio de Sanidad y Consumo,
Madrid, Spain.
17. Roberts J, Chandra M, Pebody R, Stuart J. 2007. Variation in incidence
of pneumococcal and meningococcal disease across Europe. Euro Surveill.
12:pii3310. http://www.eurosurveillance.org/ViewArticle.aspx?Article
Id3310.
18. Hanquet G, Perrocheau A, Kissling E, Bruhl DL, Tarragó D, Stuart J,
Stefanoff P, Heuberger S, Kriz P, Vergison A, de Greeff SC, Amato-
Gauci A, Celentano LP, ECDC Country Experts for Pneumococcal
Disease. 2010. Surveillance of invasive pneumococcal disease in 30 EU
countries: towards a European system? Vaccine 28:3920 –3928.
19. Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G,
Pérez L, Bastida M, Canduela C, Herranz Aguirre M, Garrote E,
Fletcher MA, Pérez C. 2007. Reduction in pediatric invasive pneumococ-
cal disease in the Basque Country and Navarre, Spain, after introduction
of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Micro-
biol. Infect. Dis. 26:303–310.
20. Calbo E, Díaz A, Cañadell E, Fábrega J, Uriz S, Xercavins M, Morera
MA, Cuchi E, Rodríguez-Carballeira M, Garau J, Spanish Pneumococ-
cal Infection Study Network. 2006. Invasive pneumococcal disease
among children in a health district of Barcelona: early impact of pneumo-
coccal conjugate vaccine. Clin. Microbiol. Infect. 12:867– 872. doi:10.1111
/j.1469-0691.2006.1502_1.x.
21. de Sevilla MF, García-García JJ, Esteva C, Moraga F, Hernández S, Selva
L, Coll F, Ciruela P, Planes AM, Codina G, Salleras L, Jordan I,
Domínguez A, Muñoz-Almagro C. 2012. Clinical presentation of inva-
sive pneumococcal disease in Spain in the era of heptavalent conjugate
vaccine. Pediatr. Infect. Dis. J. 31:124 –128.
22. Gutiérrez Rodríguez MA, Ordobás Gavín M, Ramírez Fernández R,
García Comas L, García Fernández C, Rodero Garduño I. 2008. Inci-
dence of pneumococcal disease in the autonomous region of Madrid
(1998 –2006). Med. Clin. (Barc.) 130:51–53. (In Spanish.)
23. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J.
2009. Emergence of a multidrug-resistant clone (ST320) among inva-
sive serotype 19A pneumococci in Spain. J. Antimicrob. Chemother.
64:507–510.
24. Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A,
Pallares R. 2009. Emergence of invasive pneumococcal disease caused
by multidrug-resistant serotype 19A among children in Barcelona. J.
Infect. 59:75– 82.
25. Rodríguez MA, González AV, Gavín MA, Martínez FM, Marín NG,
Blázquez BR, Moreno JC. 2011. Invasive pneumococcal disease: associ-
ation between serotype, clinical presentation and lethality. Vaccine 29:
5740 –5746.
26. Selva L, Ciruela P, Esteva C, de Sevilla MF, Codina G, Hernandez S,
Moraga F, García-García JJ, Planes A, Coll F, Jordan I, Cardeñosa N,
Batalla J, Salleras L, Dominguez A, Muñoz-Almagro C. 2012. Serotype
3 is a common serotype causing invasive pneumococcal disease in children
less than 5 years old, as identified by real-time PCR. Eur. J. Clin. Microbiol.
Infect. Dis. 31:1487–1495.
27. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L,
Hanquet G, Casal J, Tarragó D. 2009. Temporal trends of invasive
Streptococcus pneumoniae serotypes and antimicrobial resistance patterns
in Spain from 1979 to 2007. J. Clin. Microbiol. 47:1012–1020.
28. Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá
J, Lluch-Rodrigo JA, Pastor-Villalba E. 2011. Pharmacoeconomic assess-
ment of implementing a universal PCV-13 vaccination programme in the
Valencian public health system (Spain). Vaccine 29:9640 –9648.
Picazo et al.
1530 cvi.asm.org Clinical and Vaccine Immunology
 o
n
 O
ctober 1, 2014 by UAM
/SERVICIO
 DE DO
CUM
ENTACIO
N
http://cvi.asm
.org/
D
ow
nloaded from
 
